{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T11:26:40Z","timestamp":1794310000075,"version":"4.9.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,26]],"date-time":"2021-09-26T00:00:00Z","timestamp":1632614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,26]],"date-time":"2021-09-26T00:00:00Z","timestamp":1632614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s11096-021-01330-2","type":"journal-article","created":{"date-parts":[[2021,9,26]],"date-time":"2021-09-26T11:02:55Z","timestamp":1632654175000},"page":"172-179","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA Adverse Event Reporting System (FAERS) databases 2013\u20132020"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4852-1166","authenticated-orcid":false,"given":"Abdulrahman","family":"Alsuhibani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Alrasheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Musaab","family":"Gari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana L.","family":"Hincapie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff Jianfei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,26]]},"reference":[{"key":"1330_CR1","unstructured":"GHO | By category | Overweight \/ Obesity [Internet]. [cited 2021]. Available from: https:\/\/apps.who.int\/gho\/data\/node.main.A896?lang=en."},{"key":"1330_CR2","unstructured":"Products - Data Briefs - Number 360 - February 2020 [Internet]. [cited 2020]. Available from: https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db360.htm."},{"key":"1330_CR3","unstructured":"The State of Obesity 2020: Better Policies for a Healthier America - tfah [Internet]. [cited 2020]. Available from: https:\/\/www.tfah.org\/report-details\/state-of-obesity-2020\/."},{"key":"1330_CR4","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1001\/archinte.161.13.1581","volume":"161","author":"AE Field","year":"2001","unstructured":"Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med. 2001;161:1581\u20136.","journal-title":"Arch Intern Med"},{"key":"1330_CR5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1001\/jama.289.1.76","volume":"289","author":"AH Mokdad","year":"2003","unstructured":"Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76\u20139.","journal-title":"JAMA"},{"key":"1330_CR6","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1001\/jama.282.16.1523","volume":"282","author":"A Must","year":"1999","unstructured":"Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523\u20139.","journal-title":"JAMA"},{"key":"1330_CR7","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/sj.ijo.0800632","volume":"22","author":"J Cairney","year":"1998","unstructured":"Cairney J, Wade TJ. Correlates of body weight in the 1994 National Population Health Survey. Int J Obes Relat Metab Disord. 1998;22:584\u201391.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"1330_CR8","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s13679-015-0169-4","volume":"4","author":"EP Williams","year":"2015","unstructured":"Williams EP, Mesidor M, Winters K, Dubbert PM, Wyatt SB. Overweight and obesity: prevalence, consequences, and causes of a growing public health problem. Curr Obes Rep. 2015;4:363\u201370.","journal-title":"Curr Obes Rep"},{"key":"1330_CR9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.amepre.2004.08.001","volume":"27","author":"RE Patterson","year":"2004","unstructured":"Patterson RE, Frank LL, Kristal AR, White E. A comprehensive examination of health conditions associated with obesity in older adults. Am J Prev Med. 2004;27:385\u201390.","journal-title":"Am J Prev Med"},{"key":"1330_CR10","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1136\/bmj.i2156","volume":"353","author":"D Aune","year":"2016","unstructured":"Aune D, Sen A, Prasad M, Norat T, Janszky I, Tonstad S, et al. BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 37.4 million deaths among 30.3 million participants. BMJ. 2016;353:2156.","journal-title":"BMJ"},{"key":"1330_CR11","doi-asserted-by":"publisher","first-page":"434","DOI":"10.7326\/0003-4819-155-7-201110040-00006","volume":"155","author":"ES Leblanc","year":"2011","unstructured":"Leblanc ES, O\u2019Connor E, Whitlock EP, Patnode CD, Kapka T. Effectiveness of primary care-relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155:434\u201347.","journal-title":"Ann Intern Med"},{"key":"1330_CR12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa066254","volume":"357","author":"L Sj\u00f6str\u00f6m","year":"2007","unstructured":"Sj\u00f6str\u00f6m L, Narbro K, Sj\u00f6str\u00f6m CD,  Karason K, Larsson B, Wedel H, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741\u201352.","journal-title":"N Engl J Med"},{"issue":"14","key":"1330_CR13","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1001\/jama.292.14.1724","volume":"292","author":"H Buchwald","year":"2004","unstructured":"Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724\u201337.","journal-title":"JAMA"},{"key":"1330_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1741-7015-11-8","volume":"11","author":"KJ Neff","year":"2013","unstructured":"Neff KJ, Olbers T, le Roux CW. Bariatric surgery: the challenges with candidate selection, individualizing treatment and clinical outcomes. BMC Med. 2013;11:8.","journal-title":"BMC Med"},{"key":"1330_CR15","unstructured":"Who is a Candidate for Bariatric Surgery? | Patients | ASMBS [Internet]. [cited 2020]. Available from: https:\/\/asmbs.org\/patients\/who-is-a-candidate-for-bariatric-surgery."},{"key":"1330_CR16","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/j.1365-2125.2009.03550.x","volume":"68","author":"BJ Sargent","year":"2009","unstructured":"Sargent BJ, Moore NA. New central targets for the treatment of obesity. Br J Clin Pharmacol. 2009;68:852\u201360.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1330_CR17","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s11695-020-04987-2","volume":"31","author":"A Elangovan","year":"2021","unstructured":"Elangovan A, Shah R, Smith ZL. Pharmacotherapy for obesity\u2014trends using a population level national database. Obes Surg. 2021;31(3):1105\u201312.","journal-title":"Obes Surg"},{"key":"1330_CR18","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1242\/dmm.009621","volume":"5","author":"RJ Rodgers","year":"2012","unstructured":"Rodgers RJ, Tsch\u00f6p MH, Wilding JPH. Anti-obesity drugs: past, present and future. Dis Model Mech. 2012;5:621\u20136.","journal-title":"Dis Model Mech"},{"key":"1330_CR19","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJM199708283370901","volume":"337","author":"HM Connolly","year":"1997","unstructured":"Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581\u20138.","journal-title":"N Engl J Med"},{"key":"1330_CR20","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMoa1003114","volume":"363","author":"WPT James","year":"2010","unstructured":"James WPT, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363:905\u201317.","journal-title":"N Engl J Med"},{"key":"1330_CR21","unstructured":"Abbott Withdraws Sibutramine From Market [Internet]. [cited 2020]. Available from: https:\/\/www.medscape.com\/viewarticle\/730155."},{"key":"1330_CR22","unstructured":"Lorcaserin (Belviq) Withdrawn From US Market Due to Cancer Risk [Internet]. [cited 2020]. Available from: https:\/\/www.medscape.com\/viewarticle\/925253."},{"issue":"3","key":"1330_CR23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1517\/14740338.2012.675326","volume":"11","author":"G Derosa","year":"2012","unstructured":"Derosa G, Maffioli P. Anti-obesity drugs: a review about their effects and their safety. Expert Opin Drug Saf. 2012;11(3):459\u201371.","journal-title":"Expert Opin Drug Saf"},{"key":"1330_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/00325481.2018.1435129","volume":"130","author":"DK Patel","year":"2018","unstructured":"Patel DK, Stanford FC. Safety and tolerability of new-generation anti-obesity medications: a narrative review. Postgrad Med. 2018;130:173\u201382.","journal-title":"Postgrad Med"},{"key":"1330_CR25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s13679-018-0300-4","volume":"7","author":"G Srivastava","year":"2018","unstructured":"Srivastava G, Apovian C. Future pharmacotherapy for obesity: new anti-obesity drugs on the horizon. Curr Obes Rep. 2018;7:147\u201361.","journal-title":"Curr Obes Rep"},{"key":"1330_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1472-6904-9-4","volume":"9","author":"L Aagaard","year":"2009","unstructured":"Aagaard L, Hansen EH. Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics SSRIs and NSAIDs. BMC Clin Pharmacol. 2009;9:4.","journal-title":"BMC Clin Pharmacol"},{"key":"1330_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40780-017-0088-5","volume":"3","author":"H Hatahira","year":"2017","unstructured":"Hatahira H, Abe J, Hane Y, Matsui T, Sasaoka S, Motooka Y, et al. Drug-induced gingival hyperplasia: a retrospective study using spontaneous reporting system databases. J Pharm Health Care Sci. 2017;3:19.","journal-title":"J Pharm Health Care Sci"},{"key":"1330_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40780-015-0015-6","volume":"1","author":"Y Kato","year":"2015","unstructured":"Kato Y, Umetsu R, Abe J, Ueda N, Nakayama Y, Kinosada Y, et al. Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports. J Pharm Health Care Sci. 2015;1:15.","journal-title":"J Pharm Health Care Sci"},{"key":"1330_CR29","unstructured":"Questions and Answers on FDA\u2019s Adverse Event Reporting System (FAERS) | FDA [Internet]. [cited 2021]. Available from: https:\/\/www.fda.gov\/drugs\/surveillance\/questions-and-answers-fdas-adverse-event-reporting-system-faers."},{"key":"1330_CR30","unstructured":"Drugs@FDA: FDA-Approved Drugs [Internet]. [cited 2020]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/."},{"key":"1330_CR31","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2165\/00002018-200023060-00004","volume":"23","author":"M Lindquist","year":"2000","unstructured":"Lindquist M, St\u00e5hl M, Bate A, Edwards IR, Meyboom RH. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf. 2000;23:533\u201342.","journal-title":"Drug Saf"},{"key":"1330_CR32","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/ijo.2016.135","volume":"40","author":"L Aagaard","year":"2016","unstructured":"Aagaard L, Hallgreen CE, Hansen EH. Serious adverse events reported for antiobesity medicines: postmarketing experiences from the EU adverse event reporting system EudraVigilance. Int J Obes. 2016;40:1742\u20137.","journal-title":"Int J Obes"},{"key":"1330_CR33","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/BF03262002","volume":"35","author":"L Aagaard","year":"2012","unstructured":"Aagaard L, Strandell J, Melskens L, Petersen PS, Hansen EH. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBaseTM. Drug Saf. 2012;35:1171\u201382.","journal-title":"Drug Saf"},{"key":"1330_CR34","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1001\/archinte.165.12.1363","volume":"165","author":"DK Wysowski","year":"2005","unstructured":"Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969\u20132002: the importance of reporting suspected reactions. Arch Intern Med. 2005;165:1363\u20139.","journal-title":"Arch Intern Med"},{"key":"1330_CR35","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1001\/jama.2016.7602","volume":"315","author":"R Khera","year":"2016","unstructured":"Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315:2424\u201334.","journal-title":"JAMA"},{"key":"1330_CR36","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000430433","volume":"9","author":"M Kose","year":"2015","unstructured":"Kose M, Emet S, Akpinar TS, Ilhan M, Gok AF, Dadashov M, et al. An unexpected result of obesity treatment: orlistat-related acute pancreatitis. Case Rep Gastroenterol. 2015;9:152\u20135.","journal-title":"Case Rep Gastroenterol"},{"key":"1330_CR37","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/j.1467-789X.2009.00581.x","volume":"10","author":"K Johansson","year":"2009","unstructured":"Johansson K, Neovius K, DeSantis SM, R\u00f6ssner S, Neovius M. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obes Rev. 2009;10:564\u201375.","journal-title":"Obes Rev"},{"key":"1330_CR38","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","volume":"352","author":"L Sj\u00f6str\u00f6m","year":"1998","unstructured":"Sj\u00f6str\u00f6m L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998;352:167\u201372.","journal-title":"Lancet"},{"key":"1330_CR39","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/sj.ijo.0801128","volume":"24","author":"N Finer","year":"2000","unstructured":"Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord. 2000;24:306\u201313.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"1330_CR40","unstructured":"Medications Target Long-Term Weight Control | FDA [Internet]. [cited 2021]. Available from: https:\/\/www.fda.gov\/consumers\/consumer-updates\/medications-target-long-term-weight-control."},{"key":"1330_CR41","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/nrendo.2017.122","volume":"14","author":"G Srivastava","year":"2018","unstructured":"Srivastava G, Apovian CM. Current pharmacotherapy for obesity. Nat Rev Endocrinol. 2018;14:12\u201324.","journal-title":"Nat Rev Endocrinol"},{"key":"1330_CR42","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/phar.1342","volume":"33","author":"C Hampp","year":"2013","unstructured":"Hampp C, Kang EM, Borders-Hemphill V. Use of prescription antiobesity drugs in the United States. Pharmacotherapy. 2013;33:1299\u2013307.","journal-title":"Pharmacotherapy"},{"key":"1330_CR43","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","volume":"377","author":"KM Gadde","year":"2011","unstructured":"Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341\u201352.","journal-title":"Lancet"},{"key":"1330_CR44","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/oby.2011.330","volume":"20","author":"DB Allison","year":"2012","unstructured":"Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, et al. Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20:330\u201342.","journal-title":"Obesity (Silver Spring)"},{"key":"1330_CR45","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/nyas.13542","volume":"1411","author":"A Velazquez","year":"2018","unstructured":"Velazquez A, Apovian CM. Updates on obesity pharmacotherapy. Ann N Y Acad Sci. 2018;1411:106\u201319.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"1330_CR46","doi-asserted-by":"publisher","first-page":"208","DOI":"10.5534\/wjmh.200010","volume":"39","author":"YJ Tak","year":"2021","unstructured":"Tak YJ, Lee SY. Anti-obesity drugs: long-term efficacy and safety: an updated review. World J Men\u2019s Health. 2021;39(2):208.","journal-title":"World J Men\u2019s Health"},{"issue":"879","key":"1330_CR47","first-page":"e1","volume":"129","author":"HL Daneschvar","year":"2016","unstructured":"Daneschvar HL, Aronson MD, Smetana GW. FDA-approved anti-obesity drugs in the United States. Am J Med. 2016;129(879):e1-6.","journal-title":"Am J Med"},{"key":"1330_CR48","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jama.2013.281361","volume":"311","author":"SZ Yanovski","year":"2014","unstructured":"Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014;311:74\u201386.","journal-title":"JAMA"},{"key":"1330_CR49","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1808721","volume":"379","author":"EA Bohula","year":"2018","unstructured":"Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, et al. Cardiovascular safety of lorcaserin in overweight or obese patients. N Engl J Med. 2018;379:1107\u201317.","journal-title":"N Engl J Med"},{"key":"1330_CR50","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1002\/oby.22789","volume":"28","author":"R Kumar","year":"2020","unstructured":"Kumar R, Ryan D. Lorcaserin departs, leaving more questions than answers. Obesity (Silver Spring). 2020;28:1167\u20131167.","journal-title":"Obesity (Silver Spring)"},{"key":"1330_CR51","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.7150\/ijms.34141","volume":"16","author":"C Teng","year":"2019","unstructured":"Teng C, Walter EA, Gaspar DKS, Obodozie-Ofoegbu OO, Frei CR. Torsades de pointes and QT prolongation associations with antibiotics: a pharmacovigilance study of the FDA Adverse Event Reporting System. Int J Med Sci. 2019;16:1018\u201322.","journal-title":"Int J Med Sci"},{"key":"1330_CR52","unstructured":"Liraglutide Injection: MedlinePlus Drug Information [Internet]. [cited 2021 ]. Available from: https:\/\/medlineplus.gov\/druginfo\/meds\/a611003.html."},{"key":"1330_CR53","unstructured":"U.S. GAO - Obesity Drugs: Few Adults Used Prescription Drugs for Weight Loss and Insurance Coverage Varied [Internet]. [cited 2021]. Available from: https:\/\/www.gao.gov\/products\/GAO-19-577."}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-021-01330-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-021-01330-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-021-01330-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T10:42:56Z","timestamp":1650278576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-021-01330-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,26]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1330"],"URL":"https:\/\/doi.org\/10.1007\/s11096-021-01330-2","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,26]]},"assertion":[{"value":"21 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no commercial associations that might be a conflict of interest concerning this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}